Inflammatory disorders of muscle: Progress in polymyositis, dermatomyositis and inclusion body myositis

Current Opinion in Neurology

Volumn 17, Issue 5, 2004, Pages 561-567

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

amyloid; Cytotoxic T cells; Dermatomyositis; Inclusion body myositis; Polymyositis

Indexed keywords

ALEMTUZUMAB; ALUMINUM HYDROXIDE; AMYLOID BETA PROTEIN; AZATHIOPRINE; CD8 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LYMPHOCYTE ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; VACCINE;

CELL VACUOLE; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE MARKER; DYSTROPHY; FASCIITIS; HUMAN; IMMUNOPATHOLOGY; INCLUSION BODY MYOSITIS; INFLAMMATORY CELL; LASER MICRODISSECTION; MACROPHAGE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLE CELL; MYOSITIS; NONHUMAN; POLYMERASE CHAIN REACTION; POLYMYOSITIS; REVIEW; RHEUMATOID ARTHRITIS; SYNAPSE; T LYMPHOCYTE; UPREGULATION;

AMYLOID; DERMATOMYOSITIS; HUMANS; INFLAMMATION; MACROPHAGES; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; T-LYMPHOCYTES; VACUOLES;

EID: 6944247647     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200410000-00006     Document Type: Review

References (58)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325:1487-1498.
2. Mastaglia FL, Philips BA. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am 2002; 28:723-741.
3. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 2002; 28:779-798.
4. Dalakas MC. Understanding the immunopathogenesis of inclusion body myositis: present and future prospects. Rev Neurol 2002; 158:948-958.
5. Askanas V, Engel WK. sporadic inclusion body myositis and hereditary inclusion-body myopathies. Arch Neurol 1988; 55:915-920.
6. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705-713.
7. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292:344-347.
8. Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003; 61:288-290. An interesting editorial discussing how uncommon polymyositis is and the pitfalls in misdiagnosis when the current criteria of Bohan and Peter are applied.
9. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994; 15:269-274.
10. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies III. Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 1986; 19:112-125.
11. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971-982. An up-to-date, comprehensive review of polymyositis and dermatomyositis. The clinical, immunopathological and histological features of these disorders, the introduction of new diagnostic criteria, and an update on present and future therapies are described.
12. Dalakas MC, Hohlfeld R. Diagnostic criteria for polymyositis and dermatomyositis. Lancet 2003; 362:1762-1763. Justification is provided for the need to adopt the new diagnostic criteria and the importance of including the MHC/CD8 complex. The accuracy and easy identification of the MHC/CD8 complex is defended.
13. van der Pas J, Hengstman GJD, ter Laak HJ, et al. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004; 75:136-139. In a study of 61 patients with inflammatory myopathies and 163 controls, the authors confirmed that MHC-I expression is specific for polymyositis and is unchanged after therapy. It was concluded that MHC-I staining should be incorporated into the histological evaluation of inflammatory myopathies.
14. Civatte M, Schleinitz N, Kranner P, et al. Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM). Neuropathol Appl Neurobiol 2003; 29:546-552. The usefulness of MHC-I expression in dermatomyositis patients was emphasized.
15. Confalonieri P, Oliva L, Andreetta F, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack dysferlin: an immunopathological study. J Neuroimmunol 2003; 142:130-136. The pattern of MHC-I expression and infiltrates of CD8 cells was found to be different in dysferlinopathies compared with polymyositis. The results confirm the specificity of the MHC-I/CD8 lesion in polymyositis.
16. van der Meulen MFG, Bonner M, Hoogendijk JE, et al. Polymyositis: a diagnostic entity reconsidered. Neurology 2003; 61:316-321. A retrospective follow-up of 165 patients demonstrates that nine patients initially diagnosed with polymyositis did not have polymyositis when re-examined 6.5 years later. In spite of methodological limitations, the study confirms that polymyositis is uncommon and the Bohan and Peter criteria are obsolete.
17. Hilton-Davis D. Diagnosis and treatment of inflammatory myopathies. J Neurol Psychiatry 2003; 74 (Suppl.):25-31. A succinct review on the inflammatory myopathies with practical and thoughtful suggestions for the busy practitioner.
18. Drosos AA, Dalakas MC. Identification of macrophages in the muscle biopsy preparations: a comparative study using specific monoclonal anti-macrophage antibodies and acid phosphatase reaction. Muscle Nerve 1995; 18:242-244.
19. Seeliger S, Vogl T, Engels IN, et al. Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. Am J Pathol 2003; 163:947-956. Macrophages in inflammatory myopathies express the myeloid-related proteins MRP8 and MRP14, which exert a myocytotoxic effect in the myoblasts in vitro. In polymyositis and IBM, activated macrophages can invade muscle fibers and promote tissue destruction.
20. Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotizing myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003; 250:480-485. Eight patients with necrotizing myopathy, a multifactorial disease, had a partial to adequate response to steroids. Some patients with necrotizing myopathy may have a treatable disease.
21. Bassez G, Authier FJ, Lechapt-Zalcman E, et al. Inflammatory myopathy with abundant macrophages (IMAM): a condition sharing similarities with cytophagic histiocytic panniculitis and distinct from macrophagic myofascitis. J Neuropathol Exp Neurol 2003; 62:464-474. A new entity in which macrophages predominate in the perimysium/endomysium was described. The disease is distinct but may be associated with hemophagocytic syndrome.
22. Gherardi RK, Coquet M, Cherin P, et al. macrophagic myofasciitis: an emerging entity. Lancet 1998; 352:347-352.
23. Mantegazza R, Andreetta F, Bernasconi P, et al. Analysis of T cell receptor repertoire of muscle infiltrating T lymphocytes in polymyositis: restricted V a/b rearrangements may indicate antigen-driven selection. J Clin Invest 1993; 91:2880-2886.
24. Bender A, Ernst N, Iglesias A, et al. T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8 T cells. J Exp Med 1995; 181:1863-1868.
25. O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW. Predominant I T cell receptor variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 1994; 152:2569-2576.
26. Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time: studies in repeated muscle biopsies. Brain 2000; 123:2030-2039.
27. Nishio J, Suzuki M, Miyasaka N, Kohsaka H. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 2001; 167:4051-4058.
28. Benveniste O, Cherin P, Maisonobe T, et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol 2001; 167:3521-3529.
29. Behrens L, Kerschensteiner M, Misgeld T, et al. Human muscle cells express a functional costimulatory molecule distinct from B7.1 and B7.2 in vitro and in inflammatory lesions. J Immunol 1998; 161:5943-5951.
30. Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNA in inflammatory myopathies. Am J Pathol 1999; 155:453-460.
31. Goebels N, Michaelis D, Engelhardt M, et al. Differential expression of perform in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996; 97:2905-2910.
32. Figarella-Branger D, Civate M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003; 28:659-682. A comprehensive, up-to-date review on the role of cytokines, chemokines and upregulated adhesion molecules in inflammatory myopathies. Their significance in applying specific therapies was noted.
33. Choi Y, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000; 54:65-71.
34. Hofbauer M, Wiesner S, Babbe H, et al. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR and CDR3 spectratype analysis. Proc Natl Acad Sci U S A 2003; 100:4090-4095. A proof-of-principle study confirms, using a combination of spectratyping with single-cell polymerase chain reaction, that in polymyositis there is clonal expansion of autoinvasive T cells that could be identified and tracked in blood and muscle.
35. Muntzing K, Lindberg C, Moslemi AR, Oldorfs A. Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 2003; 58:195-200. This study confirms that in IBM the autoinvasive T cells are clonally expanded and certain clones persist for many years even in different muscles. It is concluded that in IBM there is a continuous antigen-driven T-cell response validating previous findings.
36. Wiendel H, Mitsdoerffer M, Schneider D, et al. Muscle fibers and cultured muscle cells express the B7.1/2 related costimulatory molecule ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003; 126:1026-1035. Muscle fibers from polymyositis, dermatomyositis and IBM express ICOS ligand, a distinct functional co-stimulatory molecule, providing further evidence that in inflammatory myopathies the muscle fibers may function as APCs.
37. Wiendl H, Mitsdoerffer M, Schneider D, et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 2003; 17:1892-1894. The inhibitory co-stimulatory molecule B7-H1 was expressed in inflammatory myopathies, and may protect muscle fibers from immune aggression.
38. Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis. Arthritis Rheum 2004; 50:199-208. Immature dendritic cells along with their CCL20/CCR6 chemokine/receptor complexes on the lymphocytic infiltrates were found for the first time within the endomysial infiltrates in polymyositis and dermatomyositis. A model in which dendritic cells, T cells and chemokines interact and lead to amplification of the inflammatory process is proposed.
39. Howard OM, Dong HF, Yang D, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002; 196:781-791. Jo-1 antigen, probably liberated from the muscle, may act as a chemoattractant for recruiting mononuclear cells and perpetuate the development of myositis.
40. Lindvall B, Dahlbom K, Henriksson KG, et al. The expression of adhesion molecules in muscle biopsies: the LFA-1/VLA-4 ration in polymyositis. Acta Neurol Scand 2003; 107:134-141.
41. Chevrel G, Page G, Granet C, et al. Interleukin-17 increases the effects of IL-β on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003; 137:125-133. Cytokines produced by T cells (IL-17) and myocytes (IL-1β) may act in combination to enhance the production of inflammatory mediators in polymyositis and dermatomyositis.
42. Raju R, Vasconcelos O, Granger R, Dalakas MC. Expression of IFN-γ-inducible chemokines in inclusion body myositis. J Neuroimmunol 2003; 141:125-131. In sporadic IBM, the IFN-γ-induced chemokines Mig and IP-10 are highly expressed and upregulated in vitro by IFN-γ. The receptor for Mig, CXCR3, was expressed only by a subset of CD8 autoinvasive cells participating in the cytotoxic process. The in-situ production of these chemokines may play a role in the continuous recruitment of T cells to the muscle.
43. Marino M, Scuderi F, Mannella F, Bartoccioni E. TGF-β-induced membrane and soluble ICAM-1 in human myoblasts. J Neuroimmunol 2003; 134:151-157.
44. Kao A, Lacomis D, Lucas M, et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50:209-215. The anti-SRP autoantibody was found to be non-specific for polymyositis because it was also observed in patients without myositis. Contrary to previous reports, the findings conclude that these antibodies are not specific for polymyositis and they are not associated with severe cardiac disease.
45. Nemoto H, Bhopale MK, Constantinrscu CS, et al. Skeletal muscle myosin is the autoantigen for experimental autoimmune myositis. Exp Mol Pathol 2003; 74:238-243. Experimental myositis was developed in mice immunized with myosin. Histologically, the muscle inflammation was similar to human disease. The animals developed myosin-specific T cells but no muscle weakness.
46. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. In: Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison's principles of internal medicine, 16th ed. New York, NY: McGraw-Hill; 2004. In press.
47. Fidzianska A, Rowinska-Marcinska K, Hausmanowa-Petrusewicz I. Coexistence of X-linked recessive Emery-Dreifuss muscular dystrophy with inclusion body myositis-like morphology. Acta Neuropathol 2004; 104:197-203. Vacuoles, identical to those seen in sporadic IBM, were found in Emery-Dreifuss muscular dystrophy. The authors conclude that the pathological features of vacuolization are not specific for IBM, but can be present in other myopathies.
48. Semino-Mora C, Dalakas MC. Rimmed vacuoles with B-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (post-poliomyelitis muscular atrophy): similarities with inclusion body myositis. Human Pathol 1988; 29:1128-1133.
49. Vattemi G, Engel W, McFerrin J, et al. BACE1 and BACE2 in pathologic and normal human muscle. Exp Neurol 2003; 179:150-158. BACE and BACE2, two enzymes participating in the processing of β-APP were accumulated in the vacuoles of IBM muscles and in necrotizing fibers, suggesting a broader function of these enzymes in myopathic processes.
50. Vattemi G, Engel W, McFerrin J, Askanas V. Cystatin C colocalized with amyloid-β and coimmunoprecipitates with amyloid-β precursor protein in sporadic inclusion-body myositis muscles. J Neurochem 2003; 85:1539-1546. Cystatic C, an endogenous cysteine-protease inhibitor, co-localized with β-APP in IBM muscle. It was proposed that cystatin C may influence β-APP processing and the deposition of β-amyloid.
51. Dalakas MC. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998; 55:1509-1512.
52. Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J Clin Invest 2003; 114:415-422. T cells reactive with the self-antigen β-amyloid 16-33 amyloid peptide were found in older people and in patients with Alzheimer's disease. The findings may be important in aging and immunosenescence because, in spite of the decline in T-cell reactivity with aging, the β-amyloid-reactive T cells are increased. The observation could be relevant in IBM, and provide the impetus to examine if β-amyloid is a putative antigen.
53. Monosomego A, Weiner H. Immunotherapeutic approaches to Alzheimer's disease. Science 2003; 302:834-838.
54. Dalakas MC. Therapeutic strategies in inflammatory myopathies. Semin Neurol 2003; 23:199-206. An up-to-date review on present and future therapies in polymyositis, dermatomyositis, and IBM.
55. Mastalgia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003; 27:407-425. A comprehensive review in inflammatory myopathies with emphasis on diagnosis and therapies.
56. Hengstman G, van den Hoogen F, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003; 50:10-15. Two patients, one with dermatomyositis and another with polymyositis, responded to the anti-TNF-α monoclonal antibody, infliximab.
57. Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology 2003; 42:1568-1569. Polymyositis developed in a patient with rheumatoid arthritis treated with infliximab, suggesting caution in considering such therapy in polymyositis and dermatomyositis without previous controlled studies.
58. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003; 61:260-262. An interesting study demonstrating that anti-T-lymphocytic globulin can be beneficial to patients with sporadic IBM. The study provides further support that intense immunotherapies against T cells may be promising in sporadic IBM.